Study on the Safety and Effectiveness of Varian ProBeam Proton Therapy Equipment in the Treatment of Solid Tumors

This study is a clinical trial of prospective, single-arm objective performance criteria. This trial will be conducted in clinical trial sites with a total of 47 subjects enrolled. All of subjects will be treated with radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam), aim to compare the data with objective performance criteria (OPC) to evaluate the effectiveness and safety of ProBeam radiotherapy system for oncology patients, providing a clinical basis for the medical device registration.

Study Overview

• Status: Completed
• Conditions: Solid Tumor; Proton Therapy; Radiation Therapy
• Intervention / Treatment: Device: Proton radiation therapy

Detailed Description

Oncology patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors. The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months. Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.

• Study Type: Interventional
• Enrollment (Actual): 47
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510000
      • Varian ProBeam 360

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1.18≤ age≤ 80 years;

2.First-diagnosed patients with tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs, etc. by tissue/cell pathology;

3.ECOG physical condition is graded as 0 to 2;

4.Women of childbearing had negative results in the blood pregnancy test (Human Chorionic Gonadotropin, HCG) 7 days prior to the first treatment;

5.The subject or subject's guardian is able to understand the purpose of the study, demonstrate sufficient compliance with the protocol and sign informed consent form

Exclusion Criteria:

1. The subject with radiotherapy contraindications, including the known genetic tendencies that increase the sensitivity of normal tissue radiotherapy or the accompanying diseases that lead to hypersensitivity to radiotherapy;
2. The subject with other uncontrolled tumors except that to be treated according to medical history or the investigator's estimation, or with other malignant tumors within five years prior to enrollment;
3. Implanted pacemakers or other metal prosthesis within the scope of proton therapy;
4. Other situations that investigator determines not suitable for enrollment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Proton radiation therapy group; Experimental: single-arm objective performance criteria, OPC	Device: Proton radiation therapy; Radiation: Proton Therapy System (ProBeam)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
tumor disease control rate reaches the objective performance criteria	After treatment, CR, PR, SD is considered disease control; Percentage of subjects who developed disease control 3 months after the end of the last radiotherapy session.	3 months ± 7 days after the last treatment
CTCAE level 3 toxic reaction ratio is lower than the acceptable value	The proportion of subjects whose toxicity reaction is level 3 during the clinical trial period. The researchers record AE that appeared during the clinical trial cycle and grade it according to CTCAE 5.0	started from subject enrollment to 3 months ± 7 days after the last treatment, up to 5 months
CTCAE level 4 and 5 toxic reaction ratio is acceptable value	The proportion of subjects with toxic reactions of levels 4 and 5 during the clinical trial period.The researchers record AE that appeared during the clinical trial cycle and grade it according to CTCAE 5.0)	the entire clinical trial ( until 3 months after last treatment)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Response (DOR)	The duration of the tumor's first assessment as CR or PR, until the first assessment of PD or death due to any cause.	screening, 1 months ± 7 days, 2 months ± 7 days, 3 months ± 7 days after the last treatment
Objective Response Rate (ORR)	The appearance of CR or PR after treatment is considered objective response, Percentage of subjects who experienced objective response at each point in time after the end of the last treatment	screening, 1 months ± 7 days, 2 months ± 7 days, 3 months ± 7 days after the last treatment
Disease Control Rate (DCR)	CR, PR, SD for disease control after treatment	screening, 1 months ± 7 days, 2 months ± 7 days, 3 months ± 7 days after the last treatment
tumor markers (if applicable), Tumor-specific symptoms	Tumor markers are examined and the researchers determine the clinical significance of reporting changes in tumor markers (before and after radiation therapy). The symptoms may be recorded according to the disease, and the researchers determine the clinical significance of reporting symptoms (before and after radiation therapy)	screening, 1 months ± 7 days, 2 months ± 7 days, 3 months ± 7 days after the last treatment
actual situation of Product usability evaluation (ProBeam system, Oncology Information system (OIS), Treatment plan system (Eclipse))	Researchers using the appropriate functions scored according to the Likert scale and collected open questions to evaluate the comprehensive feeling of ease of use during treatment.	screening, 1 months ± 7 days, 2 months ± 7 days, 3 months ± 7 days after the last treatment
CTCAE level 1 and 2 toxic reaction ratio, Adverse Events (AE) rate, Serious Adverse Events (SAE) rate	The proportion of subjects who had toxic reactions of levels 1 and 2 during the clinical trial period.The researchers record AE that appeared during the clinical trial cycle and grade it according to CTCAE 5.0	screening, 1 months ± 7 days, 2 months ± 7 days, 3 months ± 7 days after the last treatment
lab test, Eastern Cooperative Oncology Group (ECOG) grade	Conduct a laboratory examination and the researchers will judge the clinically significant changes in the reporting laboratory indicators. ECOG physical condition grading assessment, and the researchers judge the report of the results clinical significance of the change.	screening, 1 months ± 7 days, 2 months ± 7 days, 3 months ± 7 days after the last treatment
tumor recurrence rate	The rate of tumor recurrence is the ratio of the number of subjects who have relapsed to the total number of subjects. The CT or MRI imaging changes of tumors before and after treatment will be evaluated by an imaging review team based on RECIST 1.1	screening, 1 months ± 7 days, 2 months ± 7 days, 3 months ± 7 days after the last treatment

Collaborators and Investigators

• Sponsor: Guangzhou Concord Cancer Center
• Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Varian, a Siemens Healthineers Company
• Investigators: Study Director: Yimin Liu, Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Study Director: Shen Fu, Professor, Guangzhou Concord Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): December 15, 2022
• Primary Completion (Actual): July 4, 2023
• Study Completion (Actual): July 4, 2023

Study Registration Dates

• First Submitted: May 9, 2023
• First Submitted That Met QC Criteria: June 12, 2023
• First Posted (Actual): June 22, 2023

Study Record Updates

• Last Update Posted (Actual): November 7, 2023
• Last Update Submitted That Met QC Criteria: November 2, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: varian; Probeam
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: SYSQX-2022-046-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No